Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 10/27 10:00:04 pm
115.7 USD   +1.00%
06:11a JOHNSON & JOHNS : Jury awards more than $70M to woman in baby powder..
10/27 JOHNSON & JOHNS : Pinnacle Advisory Group buys $1,202,448 stake in J..
10/27 JOHNSON & JOHNS : JNJ) Faces Competition From Mylan Concerta Knockof..
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
05/07/2012 | 11:51pm CEST
   By Peter Loftus 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
06:11a JOHNSON & JOHNSON : Jury awards more than $70M to woman in baby powder lawsuit
10/27 Johnson & Johnson Reports 2016 Third-Quarter Results
10/27 Verb Surgical Inc. Honored by Goldman Sachs for Entrepreneurship - Scott Huen..
10/27 JOHNSON & JOHNSON : Jules Musing, Former Senior Executive at Johnson & Johnson, ..
10/27 JOHNSON & JOHNSON : Pinnacle Advisory Group buys $1,202,448 stake in Johnson & J..
10/27 JOHNSON & JOHNSON (NYSE : JNJ) Faces Competition From Mylan Concerta Knockoff
10/26 JOHNSON & JOHNSON : to Participate in the 25th Annual Credit Suisse Health Care ..
10/26 JOHNSON & JOHNSON : Research Reports on Drug Makers Equities -- Pfizer, Merck, A..
10/24 JOHNSON & JOHNSON : Hepatitis B Virus Market (HBV) Review with 2016-2025 Forecas..
10/24 JOHNSON & JOHNSON : Davenport Co buys $162,560,871 stake in Johnson & Johnson
More news
Sector news : Pharmaceuticals - NEC
10/27DJPFIZER : Files 8K - Changes Executive Management
10/27 ASTRAZENECA : pauses two cancer drug trials' enrolment due to bleeding
10/27DJBRISTOL MYERS SQUIBB : Makes Moves to Reassure Investors
10/27DJBRISTOL MYERS SQUIBB : Makes Moves to Reassure Investors
10/27DJApple Unveils Macs With Touch-Screen Keyboard
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/27 Should You Buy Pfizer Now?
10/26 INSIDERINSIGHTS.COM DAILY ROUND UP 1 : Cree, mcc, reed, erc
10/26 GLOBAL BLOOD THERAPEUTICS : Incredible Value At This Price
10/26 Create Your Own Johnson & Johnson Dividend
10/26 After Positive P2B Results, Tiny, De-Risked Genocea Is Severely Undervalued
Financials ($)
Sales 2016 72 080 M
EBIT 2016 21 940 M
Net income 2016 16 371 M
Finance 2016 19 430 M
Yield 2016 2,71%
P/E ratio 2016 19,58
P/E ratio 2017 17,26
EV / Sales 2016 4,12x
EV / Sales 2017 3,84x
Capitalization 316 541 M
More Financials
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 9,2%
Consensus details
EPS Revisions
More Estimates Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON12.64%316 541
ROCHE HOLDING LTD.-18.05%200 403
PFIZER INC.0.62%197 012
NOVARTIS AG-17.97%188 860
MERCK & CO., INC.16.04%169 480
SANOFI-12.39%96 780
More Results